Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

NCT03379727 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

301

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Midostaurin
DRUG: Cytarabine
DRUG: anthracycline ((daunorubicin or idarubicin): Induction Phase only

Sponsor

Novartis Pharmaceuticals